ANDAORALTABLET1 Generic Approved
Approved
Oct 2012
Lifecycle
Post-LOE
Competitive Pressure
45/100
Data completeness
3/8 — Basic
IRBESARTAN AND HYDROCHLOROTHIAZIDE (irbesartan and hydrochlorothiazide) by Hikma is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 2012.
Drug data last refreshed 22h ago
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Hikma
NJ - Berkeley Heights
Worked on IRBESARTAN AND HYDROCHLOROTHIAZIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.